Gastrointestinal lymphoproliferative disorders.
Malignant lymphomas can be first detected in some patients in endoscopic biopsies of the gastrointestinal (GI) tract. However, their recognition and accurate classification often pose problems for the pathologist for several reasons. First, the small sampling size limits pattern recognition and the number of ancillary studies which can be performed. Second, the immune system of the GI tract is capable of intense hyperplastic responses which may mimic lymphoma. Third, in a fashion similar to cutaneous lesions, those in the alimentary tract may be visualized and biopsied at a very early phase in their development when differentiation into neoplasia may be incomplete. Some forms of immune response actually pass through a poorly defined transition into lymphoma. Examples of such 'dysplasia' of the gut immune system include Helicobacter gastritis, coeliac disease and multicentric lymphoid hyperplasia associated with underlying immunodeficiency. With ever increasing endoscopic scrutiny of the gut by gastroenterologists, it is not surprising that the frequency of these indeterminate cases seems to be growing. In combination with careful clinical correlation and conventional microscopic analysis, selective immunohistochemical studies currently constitute the most powerful ancillary method in the pathologist's effort to recognize and classify GI lymphomas accurately.
Banks
P M
PM
University of North Carolina at Chapel Hill and Department of Pathology, Carolinas Medical Center, Charlotte, NC 28203, USA. peter.banks@carolinahealthcare.org
D014408:Biomarkers, Tumor; D049109:Cell Proliferation; D004759:Enterochromaffin Cells / Q000473:pathology; D005753:Gastric Mucosa / Q000473:pathology*; D005770:Gastrointestinal Neoplasms / Q000737:chemistry / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D018442:Lymphoma, B-Cell, Marginal Zone / Q000737:chemistry / Q000473:pathology*
D014408:Biomarkers, Tumor